Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979388 | 0.90 | P2RX7 (0.54) | NPC1RAB9AP2RX7DRD4SIGMAR1 | |
| SCHEMBL14263103 | 0.89 | P2RX7 (0.56) | P2RX7DRD4SSTR4ALDH1A1SSTR1 | |
| SCHEMBL4981938 | 0.88 | POLB (0.51) | NPC1RAB9ADRD4POLBSIGMAR1 | |
| SCHEMBL4981471 | 0.87 | ALDH1A1 (0.64) | P2RX7DRD4SIGMAR1SSTR4ALDH1A1 | |
| SCHEMBL4982505 | 0.86 | DRD4 (0.51) | NPC1RAB9AP2RX7DRD4SSTR4 | |
| SCHEMBL4979531 | 0.85 | TYRO3 (0.54) | P2RX7DRD4SIGMAR1SSTR4ALDH1A1 | |
| SCHEMBL13746191 | 0.83 | TP53 (0.68) | P2RX7ALDH1A1TP53GAAEPHX2 | |
| SCHEMBL4980641 | 0.82 | MCHR1 (0.63) | NPC1RAB9APOLBSIGMAR1SSTR4 | |
| SCHEMBL4983338 | 0.81 | SIGMAR1 (0.55) | P2RX7DRD4POLBSIGMAR1SSTR4 | |
| SCHEMBL14263114 | 0.81 | DRD4 (0.73) | RAB9ADRD4POLBGAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | NPC1 4132/4885RAB9A 1386/4885P2RX7 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.